<DOC>
	<DOCNO>NCT00887211</DOCNO>
	<brief_summary>A single blind , multi-center , randomize study preform compare ProStent drug-eluting stent Firebird drug-eluting stent MicroPort Medical ( Shanghai ) Co. , Ltd. evaluate safety efficacy ProStent drug-eluting stent treat coronary artery lesion .</brief_summary>
	<brief_title>ProStent Coronary Drug-Eluting Stent</brief_title>
	<detailed_description>A single blind , multi-center , randomize study preform compare ProStent drug-eluting stent Firebird drug-eluting stent MicroPort Medical ( Shanghai ) Co. , Ltd. evaluate safety efficacy ProStent drug-eluting stent treat coronary artery lesion . Appropriate patient judge inclusion exclusion standard preform stent implantation , patient clinically follow 30 , 90 , 180 , 270 365 day . Especially , standard quantity coronary angiography ( QCA ) conduct 270 day ( ±30days ) main therapeutic indicator late luminal loss ( LLL ) obtain evaluate efficacy test stent . Major adverse cardiac event ( MACEs ) find following-up period key indicator evaluate safety stent . The arrangement , conclusion statistical analysis trial data include clinography angiography fulfil independent Data Management Center ( DMC ) radiography core laboratory .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>1 . Age 1875 year , men unpregnant woman ; 2 . Angina pectoris patient nonsymptom myocardial ischemia , patient obsolete myocardial infarction ; 3 . Total lesion artery ≤2 ; 4 . Lesion artery ≤30 mm length , 2.5 4.0 mm diameter ( ocular estimate ) ; 5 . Narrow level lesion artery ≥70 % diameter ( ocular estimate ) ; 6 . Amount stent implant lesion artery ≤2 ; 7 . Patients indication coronary artery bridging surgery ( coronary artery bypass transplant technique ) ; 8 . Patients know objective trial , willing sign statement inform consent join trial , willing accept fellowup 1 . Patients acute myocardial infarction recent one month ; 2 . Chronic total occlusion lesion ( TIMI 0 grade blood flow prior implantation ) , leave trunk vessel lesion , threebranch lesion need treat , fork bridge vessel lesion branch vessel whose diameter ≥2.5mm ; 3 . Severe calcific lesion twist lesion preexpanded , lesion unsuitable deliver expand stent ; 4 . Instent restenosis lesion ; 5 . Patients stent implantation his/her coronary artery within recent one year ; 6 . Severs heart failure ( NYHA III grade ) , leave ventricular ejection fraction ( LVEF ) &lt; 40 % ( supersonic inspection leave ventricular radiography ) ; 7 . Kidney functional damage prior implantation , serum creatinine level＞2.0mg/dl ; 8 . Patients hemorrhage tendency , active digestive ulcer history , cerebral hemorrhage subarachnoid hemorrhage history , cerebral apoplexy within half year , patient contraindicate platelet inhibitor anticoagulant therefore bear anticoagulation treatment ; 9 . Patients allergic aspirin , clopidogrel ticlopidine , heparin , contrast medium , rapamycin metal ; 10 . Patients whose life expectancy le 12 month ; 11 . Patients participate drug medical device clinical trial ; 12 . Patients comply clinical trial protocol ; 13 . Patients heart transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>stent</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>